Company news
Avecho Biotechnology Limited (ASX:AVE) news
Avecho Biotechnology Limited news releases on 6ix. Latest, Aug 30, 2026: Avecho enters final stage of Phase III insomnia trial
Press releases & updates
Avecho enters final stage of Phase III insomnia trial
August 30, 2026
June 2026 Quarterly Activities Report & Appendix 4C
July 28, 2026
Positive interim analysis advances Avecho Phase III insomnia program
June 29, 2026
Positive interim results from Phase III insomnia program
June 23, 2026
Receipt of Research & Development Tax Incentive
May 21, 2026
Avecho completes treatment for Phase III interim analysis
May 20, 2026
Expiry of Listed Options
May 12, 2026
March 2026 Quarterly Activities Report & Appendix 4C
April 28, 2026
Avecho completes recruitment for Phase III interim analysis
March 1, 2026
Annual Report 31 December 2025
February 27, 2026
December 2025 Quarterly Activities Report & Appendix 4C
January 29, 2026
Phase III CBD Clinical Trial Recruitment Update
December 17, 2025
AVE Secures US & EU Patent Allowances for CBD Soft-Gel
December 3, 2025
September 2025 Quarterly Activities Report & Appendix 4C
October 31, 2025
Avecho raises $2.5m via placement
October 22, 2025
Appendix 4D and Half-year Financial Report
August 28, 2025
Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial
August 11, 2025
June 2025 Quarterly Activities Report & Appendix 4C
July 29, 2025
Phase III Insomnia Trial Recruitment Update
July 28, 2025
Receipt of R&D Tax Incentive
May 28, 2025
Phase III Trial Update - New Sites Commence Recruitment
May 19, 2025
March 2025 Quarterly Activities Report & Appendix 4C
April 30, 2025
Avecho receives initial US$3M upfront payment from Sandoz
March 27, 2025
Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
March 3, 2025
Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
March 2, 2025
Trading Halt
February 27, 2025
Appendix 4E - Preliminary Final Report
February 27, 2025
Response to ASX Price Query
February 14, 2025
December 2024 Quarterly Activities Report & Appendix 4C
January 30, 2025
September 2024 Quarterly Activities Report & Appendix 4C
October 28, 2024
June 2024 Quarterly Activities Report & Appendix 4C
July 30, 2024
Chair's Address and CEO Presentation
May 30, 2024
First Patient dosed in Phase III insomnia trial
May 15, 2024
March 2024 Quarterly Activities Report & Appendix 4C
April 30, 2024
Avecho commences Phase III insomnia trial
March 25, 2024
Avecho meets TGA ahead of Phase III Clinical Trial
March 13, 2024
AVE receives final ethics approval for Phase III CBD trial
March 6, 2024
Appendix 4E and Annual Report 31 December 2023
February 29, 2024
December 2023 Quarterly Activities Report & Appendix 4C
January 30, 2024
September 2023 Quarterly Activities Report & Appendix 4C
October 30, 2023
Reinstatement to Official Quotation
August 28, 2023
Avecho raises further $6M for Phase III trial
August 28, 2023
Voluntary Suspension
August 24, 2023
June 2023 Quarterly Activities Report & Appendix 4C
July 24, 2023
AVE CBD capsule passes two-year stability milestone
June 21, 2023
AVE adds TPM cannabinoid gummies to portfolio
June 6, 2023
USPTO allows new TPM manufacturing patent
May 28, 2023
Avecho licenses TPM for use in cancer drugs
May 22, 2023
AVE commences manufacturing for Phase III trial
May 16, 2023
Results of Entitlement Offer
May 8, 2023